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Abstract
Diphtheria is now rare in most European countries but, when cases do arise, the case fatality rate is high (5–10%). Because few coun-
tries continue to routinely screen for the causative organisms of diphtheria, the extent to which they are circulating amongst different
European populations is largely unknown. During 2007–2008, ten European countries each screened between 968 and 8551 throat
swabs from patients with upper respiratory tract infections. Six toxigenic strains of Corynebacterium diphtheriae were identiﬁed: two from
symptomatic patients in Latvia (the country with the highest reported incidence of diphtheria in the European Union) and four from
Lithuania (two cases, two carriers); the last reported case of diphtheria in Lithuania was in 2002. Carriage rates of non-toxigenic organ-
isms ranged from 0 (Bulgaria, Finland, Greece, Ireland, Italy) to 4.0 per 1000 (95% CI 2.0–7.1) in Turkey. A total of 28 non-toxigenic
strains were identiﬁed during the study (26 C. diphtheriae, one Corynebacterium ulcerans, one Corynebacterium pseudotuberculosis). The
non-toxigenic C. ulcerans strain was isolated from the UK, the country with the highest reported incidence of cases due to C. ulcerans.
Of the eleven ribotypes detected, Cluj was seen most frequently in the non-toxigenic isolates and, amongst toxigenic isolates, the major
epidemic clone, Sankt-Petersburg, is still in circulation. Isolation of toxigenic C. diphtheriae and non-toxigenic C. diphtheriae and C. ulcer-
ans in highly-vaccinated populations highlights the need to maintain microbiological surveillance, laboratory expertise and an awareness
of these organisms amongst public health specialists, microbiologists and clinicians.
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Introduction
In the European region, diphtheria is rarely suspected in
patients presenting with an upper respiratory tract infection
due to the success of widespread immunization programmes.
The disease is caused by toxin-producing Corynebacterium
species: Corynebacterium diphtheriae, Corynebacterium ulcerans,
or very rarely Corynebacterium pseudotuberculosis. In vacci-
nated or partially-vaccinated individuals, diphtheria can
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE BACTERIOLOGY
present simply as a sore throat without the classic pseudo-
membrane; clinically, the disease may not be suspected, or
can be confused with other more common conditions such
as severe streptococcal sore throat [1]. Most European labo-
ratories no longer routinely screen throat swabs for coryne-
bacteria, resulting in a loss of laboratory capability in this
ﬁeld [2]. It is therefore often difﬁcult to differentiate
between surveillance systems that report low numbers
because there are genuinely few cases and surveillance sys-
tems that have low sensitivity.
In the 1990s, a dramatic resurgence of diphtheria
occurred in the newly-independent states of the former
Soviet Union. Many factors are considered to have contrib-
uted to the epidemic: reductions in vaccination coverage,
numerous contraindications to vaccination, increased adult
susceptibility, large-scale population movements, and a lack
of adequate supplies for prevention and treatment in most
affected countries [3,4]. Intensive vaccination strategies
helped to bring the resurgence under control in most areas;
however, of the countries participating in the present study,
relatively high numbers of cases (an average of 28 symptom-
atic cases each year between 2002 and 2006) are still being
reported in Latvia, predominantly from the capital city, Riga.
No cases of diphtheria were reported to the Diphtheria
Surveillance Network (DIPNET; http://www.dipnet.org) from
Bulgaria, Estonia, Finland, Greece, Ireland and Turkey in the
5 years preceding this study (2002–2006). One case of
toxigenic C. ulcerans was reported in Italy in 2002 and ﬁve
isolates of C. diphtheriae were reported in Lithuania in 2002,
but none subsequently. The UK reported between one
and eight toxigenic isolates (including respiratory/cutaneous
infections and asymptomatic carriage) of C. diphtheriae and/or
C. ulcerans each year between 2002 and 2006.
Carriage rates in highly-vaccinated populations are
expected to be low; a strong statistical association has been
demonstrated between carriage of corynebacteria and non-
protective levels of antitoxin antibodies [5]. European studies
conducted in the last decade have documented carriage rates
of 0.5 per 1000 (for toxigenic C. diphtheriae within routine
throat swabs from Greek children) [6], and 0.7 per 1000
population (for non-toxigenic C. diphtheriae in an Italian pop-
ulation with sore throats) [7]. A Latvian study, which
screened 38 157 throat swabs from both healthy and non-
healthy individuals between 2002 and 2006, generated 140
C. diphtheriae isolates; 86% were toxigenic strains giving a
carriage rate for C. diphtheriae in Latvia (both toxigenic and
non-toxigenic organisms) of 3.7 per 1000 population [8]. Of
the countries participating in this study, only clinicians in Lat-
via routinely request screening for corynebacteria when sub-
mitting a throat swab. In the UK, routine screening for
corynebacteria is only undertaken by selected laboratories;
in the remaining participant countries, screening would only
be undertaken to investigate a suspected case, although
some countries (Lithuania, Ireland) have increased their
screening practices subsequent to the present study being
undertaken.
Widening membership of the European Union has lead to
signiﬁcant migration of Eastern European populations to live
and work in many parts of Western Europe. The present
study attempts to determine the current prevalence of
potentially toxigenic corynebacteria in different European
populations to help with the interpretation of any future
changes in the epidemiology of these infections in Europe.
Materials and Methods
Ten countries participated in this screening study, represent-
ing Baltic (Estonia, Latvia, Lithuania), Northern (Finland),
Western (Ireland, UK), Southern (Italy, Greece) and Eastern
(Bulgaria, Turkey) European countries.
Between December 2007 and June 2008, participating lab-
oratories in each country processed throat swabs routinely
received from patients with upper respiratory tract infec-
tions for potentially toxigenic corynebacteria, regardless of
any other clinical indication. The exact screening periods for
each individual laboratory varied in the range 1–5 months.
The number of participating laboratories in each country
ranged from one (in Finland) to 16 (in Greece) (Table 1).
Information on symptoms, vaccination history, travel his-
tory, and management of the case and contacts was com-
pleted for each patient in whom a toxigenic strain was
identiﬁed using a case follow-up questionnaire. Patients from
whom a non-toxigenic strain was isolated were not fol-
lowed-up.
Statistical analysis
It was calculated that a minimum sample size of 2700 swabs
per country was required to estimate, with reasonable preci-
sion, a prevalence similar to that previously seen in Latvia
(described above) of 3.7 per 1000 population (a 95% CI length
of <5 per 1000) [8]. Exact 95% CIs for carriage rates were cal-
culated and the effects of country, age and sex were investi-
gated in univariable analyses using Fisher’s exact test and, in
multivariable analyses, by logistic regression, using STATA soft-
ware, version 8.0 (Stata Corp., College Station, TX, USA).
Laboratory analysis
All participating countries processed throat swabs for poten-
tially toxigenic corynebacteria according to their standard
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protocols and WHO guidelines [9]. Most countries per-
formed primary screening using Hoyle’s tellurite at the local
laboratory level, and suspect colonies were sent to the coun-
try’s reference centre for further conﬁrmation of identiﬁca-
tion and toxigenicity.
At the end of the screening period, all C. diphtheriae,
C. ulcerans and C. pseudotuberculosis isolates identiﬁed during
the study were sent to the HPA Respiratory & Systemic
Infections Department in London, UK, for conﬁrmation and
molecular typing (ribotyping) [10].
Results
The number of swabs examined by each country during the
screening period ranged from 968 (Italy) to 8551 (UK)
(Table 2). Generally, more throat swabs were screened from
females than males. Swabs submitted from children’s hospi-
tals were included for Estonia, Ireland, Lithuania, Latvia and
Turkey; in Greece, only children were screened.
Toxigenic C. diphtheriae strains were isolated in Latvia
and Lithuania, giving carriage rates of 0.8 per 1000 (95% CI
0.1–2.9) and 0.7 (95% CI 0.1–2.4), respectively. Carriage
rates of toxigenic strains were zero in all other countries,
although the upper 95% CI ranges varied from 0.4 per
1000 in the UK to 3.8 per 1000 in Italy. Toxigenic C. diph-
theriae carriage rates did not signiﬁcantly differ by country,
age or sex.
Non-toxigenic C. diphtheriae carriage estimates ranged
from 0 (Bulgaria, Finland, Greece, Italy, Ireland) to 4.0 per
1000 in Turkey (95% CI 2.0–7.1). In the multivariable analy-
sis (including all countries), non-toxigenic C. diphtheriae car-
riage rates varied between countries (p <0.001), sex (p
0.03) and age (p 0.03); however, after excluding Turkey,
which had a cluster of seven males and two females aged
5–14 years, there was no difference by sex (p 0.14) but dif-
ferences remained between countries (p <0.001) and there
was some evidence, although not signiﬁcant, of a difference
by age (p 0.05), with the highest rates in the 15–44 years age
groups.
Toxigenic cases: additional information from follow-up
questionnaires
Both Latvian cases were 14 year olds presenting with sore
throats; one (CaseLV2) also had a fever. CaseLV1 had
completed primary diphtheria vaccinations, whereas
CaseLV2 had received only two doses (in 2002 and 2003,
respectively). In Latvia, primary diphtheria vaccination is
scheduled at 3, 4 and 6 months of age, with boosters at
18 months, 7 and 14 years. The cases were unlinked and
there was no history of travel or known risk factors identi-
ﬁed. Both patients received antibiotics. No diphtheria anti-
toxin was administered due to the mild clinical course,
although Latvia does maintain a stock. Close contacts for
both cases (two for CaseLV1, 37 for CaseLV2) were nega-
tive for C. diphtheriae. Contact tracing swabs are not
included in Table 2.
Both Lithuanian cases presented with classic respiratory
diphtheria with a pseudomembrane; neither had a history of
travel, nor a link to another conﬁrmed case. The fatal case
was an unvaccinated 61-year-old woman (CaseLT1) who
lived in crowded conditions with inadequate nutrition. She
presented with a sore throat, pseudomembrane and fever,
swelling and oedema of the neck, and submucosal or skin
petechial haemorrhages; she also had underlying autoimmune
thyroiditis and grade 4 aortic atherosclerosis. Eighty contacts
were swabbed, two of whom were carriers of toxigenic
C. diphtheriae (CarrierLT1 and CarrierLT2); one unimmu-
nized and the other with vaccination status unknown. The
second Lithuanian case, a 15-year-old female (CaseLT2), was
immunized (completed primary immunization, last high dose
booster of diphtheria was received in 2001, next booster
would be scheduled at 15–16 years of age) with no other
known risk factors. All twenty-two close contacts for
TABLE 1. Participating laboratories and regions in each country
Country
Number of
laboratories Areas served by participating laboratories
Bulgaria 4 Soﬁa area
Estonia 11 Whole country
Finland 1 Helsinki area
Greece 16 Ten laboratories from the Greater Athens area, other laboratories from Central and Northern Greece, Thessalia, and Crete
Italy 3 Rome, Perugia and Palermo
Ireland 3 Dublin North, Dublin South West, and part of Cork
Latvia 2 Whole country
Lithuania 13 Kaunas, Panevezys, Alytus, Vilnius, Siauliai, Marijampole and Klaipeda counties
Turkey 12 Adana, Ankara, Diyarbakir, Erzurum, Izmir, Istanbul, Samsun and Sanliurfa provinces
UK 12 Central and South Manchester, South and West Bristol, Cambridge, West Suffolk, Leicestershire, Southampton,
East Birmingham, Newcastle, North East Derbyshire and part of South Yorkshire, Mid Essex, West Norfolk and Fenland, Bedfordshire
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CaseLT2 were negative for C. diphtheriae. Both patients
received antibiotics [CaseLT1 Cefuroxime (1 day) then imip-
enem and cilastatin sodium (½ day), CaseLT2 Cefazolin
(15 days) then Gentamicin (10 days)]. The carriers received
antibiotics (erythromycin) and diphtheria vaccine. Neither
case received diphtheria antitoxin; Lithuania does not cur-
rently hold a stock of diphtheria antitoxin because of pro-
curement difﬁculties [11].
Microbiological characterization of isolates
All toxigenic isolates were biotype gravis; one Latvian strain
was not available to ascertain the ribotype and the other
(CaseLV2) was Sankt-Petersburg; all four Lithuanian strains
were also Sankt-Petersburg (Table 3). Biotyping and ribo-
typing was also performed on the non-toxigenic isolates: 12
of 26 C. diphtheriae were biotype var gravis, ten of 26 were
var mitis, and two of 26 were var belfanti (two were not avail-
able for further characterization). Of the 86 ribotypes that
have been previously identiﬁed and validated from over 25
countries, Cluj was detected in Latvia and Turkey, Buzau in
the UK, Moskva in Lithuania, Romania in Estonia, and Lithua-
nia and Lyon in Turkey. A new ribotype was also identiﬁed
in Turkey, which matched closest to Constantine. The non-
toxigenic C. ulcerans isolate detected in the UK was ribotype
U4 (a different nomenclature to C. diphtheriae ribotyping)
[12]. The C. pseudotuberculosis isolate from Latvia did not
undergo ribotyping. The non-toxigenic isolates were also
tested for the presence of the diphtheria toxin gene; the
two isolated from Lithuania (ribotype: Moskva) were toxin-
gene positive, all the others were negative. These two strains
are designated as non-toxigenic toxin-gene bearing strains
(NTTBs); the gene is present but the toxin is not expressed
and are thus negative when examined in the Elek phenotypic
test [9].
TABLE 3. Isolates detected during screening period
Country Age group (years) Sex Organism Biotype Ribotype Comment
Toxigenic isolates
Latvia 5–14 M Corynebacterium diphtheriae var gravis NA CaseLV1
Latvia 5–14 F C. diphtheriae var gravis Sankt-Petersburg CaseLV2
Lithuania 45–64 F C. diphtheriae var gravis Sankt-Petersburg CaseLT1
Lithuania 25–44 M C. diphtheriae var gravis Sankt-Petersburg CarrierLT1 (Contact of CaseLT1) - not included
in the screening study as asymptomatic
Lithuania 15–24 M C. diphtheriae var gravis Sankt-Petersburg CarrierLT2 (Contact of CaseLT1) - not included
in the screening study as asymptomatic
Lithuania 15–24 F C. diphtheriae var gravis Sankt-Petersburg CaseLT2
Country Age group (years) Sex Organism Biotype Ribotype Tox PCR result
Non-toxigenic isolates
Estonia 15–24 F C. diphtheriae var belfanti Romania Negative
Latvia 0–4 M C. diphtheriae var gravis Cluj Negative
Latvia 5–14 M C. diphtheriae var mitis Cluj Negative
Latvia 15–24 M C. diphtheriae var gravis Cluj Negative
Latvia 15–24 M C. diphtheriae var gravis Cluj Negative
Latvia 45–64 M C. diphtheriae NA NA NA
Latvia 15–24 F C. diphtheriae NA NA NA
Latvia 25–44 F Corynebacterium pseudotuberculosis – – Negative
Latvia 45–64 F C. diphtheriae var gravis Erlabrunn Negative
Lithuania 15–24 M C. diphtheriae var mitis Moskva Positive; NTTB
Lithuania 25–44 M C. diphtheriae var mitis Otchakov Negative
Lithuania 25–44 F C. diphtheriae var mitis Moskva Positive; NTTB
Lithuania 25–44 F C. diphtheriae var befanti Romania Negative
Turkey 5–14 M C. diphtheriae var gravis Cluj Negative
Turkey 5–14 M C. diphtheriae var mitis Cluj Negative
Turkey 5–14 M C. diphtheriae var mitis St Albans Negative
Turkey 5–14 M C. diphtheriae var gravis Cluj Negative
Turkey 5–14 M C. diphtheriae var mitis Cluj Negative
Turkey 5–14 M C. diphtheriae var mitis Cluj Negative
Turkey 5–14 M C. diphtheriae var gravis Cluj Negative
Turkey 45–64 M C. diphtheriae var gravis Lyon Negative
Turkey 5–14 F C. diphtheriae var mitis Closest to
Constantine/NT
Negative
Turkey 5–14 F C. diphtheriae var gravis Cluj Negative
Turkey 45–64 F C. diphtheriae var gravis Lyon Negative
UK 25–44 M C. diphtheriae var mitis Pamiers Negative
UK 25–44 M C. diphtheriae var gravis Buzau Negative
UK 15–24 F C. diphtheriae var gravis Buzau Negative
UK 5–14 M Corynebacterium ulcerans – – Negative
NA, not available; NT, new type; NTTB, non-toxigenic toxin-gene bearing.
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Discussion
This is the ﬁrst large multicentre European screening study
to be undertaken for corynebacteria, with throat swabs col-
lected and screened during a 7-month period. The differing
numbers of swabs screened by each country were inﬂuenced
by population size, consulting rates, and the different proba-
bilities of a throat swab being taken for patients presenting
with a sore throat. None of the countries with sample sizes
below 1300 detected any C. diphtheriae or C. ulcerans, sug-
gesting that there may have been insufﬁcient power in these
studies to detect the low levels of carriage found in the
other countries.
All participating countries schedule at least ﬁve doses of
diphtheria vaccine in their vaccination programmes, although
the composition (low/high dose) and administration age var-
ies. Vaccination coverage estimates for participating countries
are high; estimates for Latvia and Lithuania over the last dec-
ade show over 90% coverage at 2 years of age for the ﬁrst
three doses of DTP (diphtheria, tetanus, pertussis) vaccine,
with 98% and 95% coverage respectively reported in 2007
(http://www.who.int/immunization_monitoring/en/globalsum-
mary/timeseries/tscoveragedtp3.htm; accessed 30 July 2009).
It should be noted, however, that different methods of
assessment of coverage are employed in different countries
and, although the overall coverage may be high, pockets of
low coverage can still exist. A large-scale seroepidemiology
study conducted across seven European countries between
1995 and 1998 found that 70–75% of adults aged 50–
60 years from the UK had diphtheria antitoxin antibody
titres below the putative lower protection threshold com-
pared to approximately 35% of Finnish adults of the same
age [13]. The proportion of seronegative adults (aged
30 years and above) in Italy was approximately 28% at the
time of the study, and expected to increase. Waning immu-
nity with age coupled with proportions of unvaccinated
adults can lead to a susceptible population in older age
groups.
Training workshops were conducted just prior to this
study in Turkey and Estonia, and during the ﬁnal stages of
the study in Latvia; these countries all detected C. diphtheriae
strains. In the UK, three of four non-toxigenic organisms
detected were isolated by the West Suffolk microbiology lab-
oratory, which screened the second largest number of swabs
and was the only laboratory from which a microbiologist had
recently attended a diphtheria diagnostics workshop. The
other non-toxigenic C. diphtheriae was isolated from a UK
laboratory that has a routine screening policy for corynebac-
teria. The absence of a screening policy and a lack of recent
training in other centres may have resulted in an overall
under-estimation of carriage rates nationally.
One of the major clones causing the 1990s epidemic in
the European region was a toxigenic C. diphtheriae var gravis,
ribotype Sankt-Petersburg [14]. Recent studies have shown
that this ribotype is still circulating and causing disease in
Russia, Belarus and Latvia [15,16]. This screening study
detected Sankt-Petersburg isolates from Latvia and Lithuania.
In addition, ribotyping of concurrent isolates from Latvia that
had caused diphtheria-like disease revealed the Sankt-Peters-
burg ribotype, highlighting the persistence of a highly success-
ful and virulent clone. The majority of the ribotypes seen
amongst the non-toxigenic isolates are more commonly asso-
ciated with toxigenic isolates (Cluj, Moskva, Otchakov,
Pamiers and St Albans) [10]; some have also been detected
recently from Belarus (Cluj and Moskva) [16]. These data
illustrate that persistent ribotypes are still circulating, and the
bacterial population is evolving despite high vaccine coverage,
resulting in a C. diphtheriae population that remains diverse
enough to cause both epidemic and sporadic diphtheria.
Antibiotic susceptibility testing was not undertaken on iso-
lates sent to the reference centre; these tests are usually
undertaken locally. No unusual ﬁndings were reported to
the co-ordinating centre, although this information was not
speciﬁcally requested. It may be interesting to explore this
area in a future study; however, the incidence of antibiotic
resistance amongst potentially toxigenic corynebacteria is
low [17].
The identiﬁcation of two cases of diphtheria from Lithua-
nia, neither of whom had any history of travel or contact
with travellers, indicates that toxigenic C. diphtheriae is circu-
lating within Lithuania. Examination of throat swabs for diph-
theria is usually funded by the state in Lithuania but, in some
cases, transportation of swabs requires payment, which may
reduce the submission of samples to diagnostic laboratories;
this could have inﬂuenced the lack of cases reported in
recent years. A similar situation exists in Latvia. One of the
toxigenic C. diphtheriae strains detected in Lithuania would
have been missed in the absence of this screening study,
highlighting the importance of screening for these organisms.
The present study has shown that NTTBs are circulating
in Lithuania; these strains have the potential to become toxi-
genic and cause more serious illness [18,19]. The isolation of
nine non-toxigenic C. diphtheriae strains in Turkey in geo-
graphically unrelated 5–14 year olds may not be unusual; in
the UK, non-toxigenic C. diphtheriae strains are often isolated
from unlinked young adults with a preponderance of females
and may reﬂect consultation rates in the general population
[20]. There is currently no direct evidence of person-to-
person transmission of C. ulcerans or C. pseudotuberculosis, so
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there is less public health concern surrounding the isolation
of these zoonotic organisms, particularly non-toxigenic
strains. Although not collected as part of the present study,
the Latvian patient from whom non-toxigenic C. pseudotuber-
culosis was isolated was known to have had contact with cats
and dogs and had also consumed untreated milk products.
The results of the present study, particularly the ﬁnding of
toxigenic C. diphtheriae in Lithuania, highlight the importance
of routine screening or further ‘snapshot’ studies within the
European Region. In addition, they reinforce the need to
achieve and maintain high vaccination coverage across the
European region, as well as to maintain laboratory expertise in
this specialized area. One of four cases identiﬁed in the study
was fatal, demonstrating the severity of this disease in unim-
munized patients, and the need to remain vigilant and aware of
its possible clinical presentations. Larger studies in the future
are essential for providing improved estimates of carriage in
European countries, and for monitoring any changes in the cir-
culation of these organisms against these baseline data.
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